Replies to post #688371 on NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

<<< In England, around 2,200 cases >>
In 10 years of C Care, NWBO got almost ZERO of them

[Single Stock]

Regardless of numbers NVCR got to $20bn m/c ….

[manibiotech]

All credible sources show new GBM cases between 2200-3000 in Uk . Yet some here keep throwing 12k without providing any credible source . Even if you include rGBM , it can’t come anywhere close to 12K

[Chiugray]

AngeloFoca, Thanks for that info.

I believe we need to view the potential market of DCVax differently from other drugs that are typically limited in terms of label expansion and off label use due to their toxicity and that they generally are only for treating sub-segments of a cancer.

Also the difference between a stage 3 brain tumor and stage 4 is just the extent of spreading in the brain. From an oncologist/patient's perspective they both require aggressive treatment.

This is where DCVax-L fits in. Because it will be approved as replacing the current SOC treatment, is non-toxic, and is a vaccine, the dynamics of off-label use will be very different and much more expansive than other cancer drugs. So I look at the potential realizable market for DCVax-L in brain tumors much more broadly. I believe they potentially will capture the entire cancer type, including the early stage benign brain tumors.

It seems to be the natural course, as it is a broad spectrum cancer vaccine, is non-toxic, and creates a more robust immune memory to fight against cancer recurrence. Everybody will demand it. DCVax changes everything.